Bevacizumab in HER2neu Negative Locally Recurrent and Metastatic Breast Cancer: The BHerN Review

Mary Ondinee U. Manalo, Mark Anthony E. Agana and Corazon A Ngelangel

Section of Medical Oncology, Department of Medicine, College of Medicine and Philippine General Hospital, University of the Philippines Manila

ABSTRACT

Introduction. A promising strategy for HER2-negative metastatic breast cancer (mBC) is to target the vascular endothelial growth factor receptor using bevacizumab. Several randomized controlled trials (RCTs) have consistently demonstrated improvement in progression-free survival (PFS).

Methods. This meta-analysis was undertaken to determine the added benefit of bevacizumab (BV) to chemotherapy in HER2-negative locally recurrent and mBC. RCTs that compared the efficacy and safety of BV+chemotherapy to placebo+chemotherapy in the first- or second-line setting were selected. The primary outcome was PFS. The secondary outcome measures were overall survival (OS) and objective response rate (ORR). Analysis of safety was done by pooling grades 3-5 toxicities. Four RCTs were included in the meta-analysis: E2100, AVADO, RIBBON-1, and RIBBON-2.

Results. The use of BV+chemotherapy showed statistically significant improvement in PFS (HR 0.73 [0.65, 0.82] 95% CI, p<0.0001); subgroup analysis of triple-negative breast cancer (TNBC) also showed statistically significant increase in PFS (HR 0.56 [0.47, 0.67] 95% CI, p<0.00001). The ORR was statistically significant with a risk ratio of 1.36 in favour of BV (p<0.0001). OS did not reach statistical significance (HR 0.85 [0.56, 1.27] 95% CI, p=0.42). Grades 3-5 toxicities were consistently higher in the BV arm with a risk ratio of 1.90 (p<0.0001).

Conclusion. BV prolongs PFS and increases ORR in patients with HER2-negative locally-recurrent and mBC. OS was comparable in both arms. Toxicities significantly increased with the addition of BV to chemotherapy, but fatal reactions were rare in all four trials. The addition of BV to conventional first- or second-line chemotherapy is justified in TN mBC since there is still no standard treatment for this.

Key Words: bevacizumab, HER2 negative, triple negative metastatic breast cancer

Introduction

Breast cancer is the most common malignancy in women worldwide. In the Philippines, more than 18,000 were diagnosed in the Manila and Rizal area in 2010. In the Cancer Institute of the Philippine General Hospital, the Breast Care Clinic and the Medical Oncology Clinic see about 60 breast cancer patients per day.

Breast cancer represents a heterogeneous malignancy that is diversified by its immune-histochemical features, behavior, outcome and response to treatment. De Vita describes that breast cancer has several molecular subtypes, namely; luminal A and B, HER2 over-expressing and basal-like breast. The human epidermal growth factor receptor 2 (HER2)/neu is a growth factor receptor gene that is amplified in approximately 20-25% of breast cancers with its corresponding encoded protein also being detected at abnormally high levels in these malignant cells. Its main function is to mediate growth, differentiation, and survival of cells. Amplification of HER2, is known to be associated with reduced disease-free and OS compared with patients with HER2-negative disease. With the introduction of trastuzumab, a monoclonal antibody directed against the HER2 receptor, both PFS and OS have improved essentially, thus changing the natural history of HER2-positive mBC.

Presently, ER/PgR-negative HER2-negative status is associated with a poorer prognosis because of lack of standard therapy. And this is even more important because 80% of breast cancers are HER2-negative.

Angiogenesis is a complex process whereby a vasculature develops that involves a balance between many stimulating and inhibitory factors. The key regulator of angiogenesis is the vascular endothelial growth factor (VEGF) and its receptor system. VEGF is essential during
early stages of tumorogenesis and plays a key role in tumor metastasis. The transition of the tumor from avascular to vascular phase, termed angiogenic phase, is said to be the hallmark of the malignant process.\(^5\) Studies on early breast cancer have showed high expression of VEGF. Its expression is responsible throughout the growth and development of the tumor, and has been associated with shorter relapse-free survival and over-all survival times in patients either with positive or negative lymph nodes. Therefore, inhibition of VEGF causes regression of the tumor vasculature, prevents neovascularization and promotes normalization of the remaining blood vessels.\(^9,10\)

One promising strategy is to target the VEGF, either by ligand sequestration or inhibiting downstream receptor. The European Medicines Agency (EMA) approved bevacizumab, a humanized monoclonal antibody directed against VEGF by ligand sequestration as a first line treatment for advanced breast cancer. It binds and neutralizes all biologically active isoforms of VEGF. It has been approved for lung cancer, renal cell cancer, colorectal cancer, glioblastoma multiforme, and for ovarian cancer.

BV+chemotherapy, particularly with taxane were shown to improve the efficacy of treatment of mBC in phase I and II trials. These studies have shown improvement of ORR and median time to progression (TTP).\(^11\) There was shown a 36% lower risk of PFS with addition of BV to chemotherapy in patients with mBC.\(^12,13\)

At present, there is no standard treatment for ER/PgR-negative HER2-negative breast cancer in the locally-recurrent and metastatic.\(^5\) New treatments that could delay disease progression without systemic toxicity would represent a significant advancement. Also, there are conflicting data on the real benefit of BV in mBC. It is in this light that this meta-analysis was done.

This study evaluates the efficacy of BV+chemotherapy versus chemotherapy alone in the treatment of locally-recurrent or metastatic HER2-negative breast cancer by measuring the PFS.

**Methods**

**Search Strategy**

The meta-analysis was performed according to a predefined protocol. To be eligible, the studies had to be Phase III clinical trials that dealt with HER2-negative metastatic or locally recurrent breast cancer. The studies should involve BV in addition to any chemotherapy versus a placebo plus chemotherapy (up to June 2012). Studies were identified by an electronic search engine using online PubMed. The search terms used were "bevacizumab", "anti-VEGF", "breast cancer", "locally recurrent breast cancer", "metastatic breast cancer" and "HER2-negative breast cancer". Another electronic search using the same key words at ClinicalTrials.gov was performed. The initial selection of articles relied on careful reading of their abstracts. Abstracts were reviewed from the American Society of Clinical Oncology proceedings as well. References from relevant literature were screened, including all of the identified studies. Trial authors were contacted to obtain the full text of some articles. Duplication of data was avoided by examining for each publication the names of all authors and the different medical centers involved. The search was limited to randomized controlled trials. No language restriction was imposed.

**Study Selection Criteria**

The reviewers browsed through the titles and abstracts of studies identified in the electronic and hand search for possible inclusion. Full texts of studies judged to be relevant were retrieved and independently assessed for inclusion by the reviewers. A study was considered relevant if it met the following inclusion criteria: it is a Phase III clinical trial; it involved adult subjects with at least a subgroup consisting of HER2-negative breast cancer; BV was used in combination with chemotherapy and was compared to placebo plus chemotherapy; PFS, OS, ORR, and adverse events were reported.

Studies that met the inclusion criteria were then evaluated for methodological quality using the Jadad scale. This was done independently by the reviewers. Conflicts were resolved by consensus.

**Data Collection and Statistical Analysis**

Data were extracted independently by the reviewers. The following data were obtained from each study: title, author and year of publication, total population of the study and the population for each treatment arm, PFS, OS, ORR, and incidence of grades 3-5 adverse events.

PFS, defined as the time from randomization to disease progression, and OS, defined as the time from randomization to death from any cause, was measured in months. ORR was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (http://www.recist.com/). Analysis of safety was also done by pooling grades 3-5 toxicities as graded by the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.0 (USA NIH-NCI, 2009). Subgroup analysis for survival data for TNBC was done. Any discrepancy between the reviewers was resolved by discussion and consensus.

The analytic approach and software provided by the Cochrane Collaboration was used for all analyses (Review Manager (RevMan) [Computer program], Version 5.0 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008. Cochrane Centre, Copenhagen, Denmark). For the quantitative measure of survival, hazard ratio and their 95% confidence interval were taken based on the data that was provided by the publication. Findings
were considered to be statistically significant if the test for overall effect has a p-value < 0.05. The risk estimates and confidence intervals were illustrated using forest plots. Heterogeneity was assessed through the $\chi^2$ test and quantified using the $I^2$ test.

The final report was written in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

**Results**

**Study Selection**

A total of 174 trials were considered for inclusion. 157 studies were excluded after the initial screening. 14 studies were excluded after review of the full texts. The final meta-analysis included a total of 4 trials in the final review with a total of 1,667 subjects who were included in the final analysis. Summarized in Figure 1 is the search and study selection process.

**Study Characteristics**

The main features of the eligible studies are summarized in Table 1. All four studies compared BV+ chemotherapy to placebo+chemotherapy. In E2100, AVADO, and RIBBON-1, BV was given as first line for mBC. RIBBON-2 tested BV as a second-line treatment. These studies did not include purely HER2-negative individuals. Some were HER2-positive and were enrolled only if they were on or have failed trastuzumab. Since the purpose of this meta-analysis was to determine the added benefit of BV to standard chemotherapy in HER2-negative mBC patients, we extracted the purely HER2-negative subsets and used these in our analysis. The main features of the excluded studies are summarized in Appendix 1. Ongoing studies are shown in Appendix 2.

**Assessment of Bias**

The four studies included in the meta-analysis were assessed for quality of methodological reporting. Studies were rated independently by the reviewers with one of the reviewers blind to the study title, name and publication details. The detailed methodological quality of the individual studies is shown in Table 2. All of the studies were judged to be of high methodological reporting quality via the Jadad scale.
## Table 1. Study RCTs

<table>
<thead>
<tr>
<th>Type of Study</th>
<th>Number of Participants</th>
<th>Inclusion</th>
<th>Exclusion</th>
<th>Study Design</th>
<th>Primary Endpoint</th>
<th>Secondary Endpoint</th>
</tr>
</thead>
</table>
| E2100 2007    | 133:118                | All kinds, majority are HER2-negative | CNS metastasis | I: Paclitaxel 90 mg/m2 on days 1,8, and 15 of a 28-day cycle + placebo  
II: Paclitaxel 90 mg/m2 on days 1,8, and 15 of a 28-day cycle + bevacizumab 10 mg/kg on days 1 and 15 continued until disease progression or with unacceptable toxicity | PFS | OS, Safety |
| AVADO 2010    | 247:219                | HER2-negative, LR or mBC | SCC | I: Docetaxel 100 mg/m2 on day 1 every 3 weeks for a max of 9 cycles + placebo  
II: Docetaxel 100 mg/m2 + bevacizumab 15 mg/kg every 3 weeks | PFS | ORR, DOR, TTP, OS, Safety |
| RIBBON-1 2011 | 177:67                 | No prior chemotherapy for advanced disease | Prior chemotherapy in the past 12 months | I: Tax/anthracycline + Placebo  
II: Tax/anthracycline + bevacizumab 15 mg/kg every 3 weeks | PFS | ORR, OS, DOR, Safety |
| RIBBON-2 2011 | 459:225                | If with previous taxane-based chemotherapy, 12 months must have elapsed before randomization | Prior chemotherapy in the past 12 months, CNS metastasis | I: Chemotherapy + Placebo  
II: Chemotherapy + bevacizumab at 10 mg/kg every 2 weeks or bevacizumab at 15 mg/kg at 3 weeks until disease progression or with unacceptable toxicity | PFS | ORR, OS, DOR, Safety |
Bevacizumab in Her2neu Negative Breast Cancer

Table 2. Risk of Bias in Studies

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sequence Generation</td>
<td>Use of permuted blocks within strata</td>
<td>Use of interactive voice response system</td>
<td>Use of interactive voice response system</td>
<td>Hierarchical dynamic randomization algorithm using an interactive voice response system</td>
</tr>
<tr>
<td>Allocation Concealment</td>
<td>Did not say</td>
<td>Did not say</td>
<td>Did not say</td>
<td>Did not say</td>
</tr>
<tr>
<td>Blinding</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Incomplete Outcome Data Addressed</td>
<td>Intention to treat analysis was done</td>
<td>Intention to treat analysis was done</td>
<td>Intention to treat analysis was done</td>
<td>Intention to treat analysis was done</td>
</tr>
<tr>
<td>Jadad</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
</tbody>
</table>

Summary of Results

Since we did not have the raw data of the studies evaluated, standard errors were derived for each of the studies. In our analysis, the use of BV+chemotherapy showed statistically significant improvement in PFS (HR 0.73 [0.65, 0.82] 95% CI, p<0.0001) (Figure 2). In E2100, RIBBON-1, and RIBBON-2, a substantial number of persons had TNBC. Subgroup analysis of this group also showed statistically significant increase in PFS (HR 0.56 [0.47, 0.67] 95% CI p<0.00001) (Figure 3). In those with measurable disease, the ORR was statistically significant with a risk ratio of 1.36 in favour of BV (p<0.00001) (Figure 4). OS was not statistically significant (HR 0.85 [0.56, 1.27] 95% CI, p=0.42) (Figure 5). Grades 3-5 toxicities were consistently higher in the BV arm with a risk ratio of 1.90 (p<0.00001) (Figure 6). The plots for PFS and ORR were all homogenous. However, the plots for OS and occurrence of toxicities were heterogenous. We attribute this to the variability of the kinds and doses of chemotherapy used together with BV.

Figure 2. PFS, HER2-negative breast cancer

Figure 3. PFS, TNBC
Bevacizumab in HER2-negative Breast Cancer

**Discussion**

In E2100, BV was shown to be superior to placebo when added to paclitaxel as the initial treatment of metastatic HER2-negative breast cancer. It concluded that treatment with BV early in the course of mBC, when angiogenic pathways are less redundant, improved PFS and the ORR. In this study, although the patients were being given their first chemotherapy in the metastatic setting, more than half already received chemotherapy in the adjuvant setting. Since then, there have been more questions than answers regarding the role of BV in advanced breast cancer.

The results of AVADO and RIBBON-1 confirmed the improvement in PFS and response rates which were earlier seen in E2100. However, the evidence was less robust in the latter two studies. RIBBON-2, designed to test the efficacy of BV in the second-line setting in HER2-negative breast cancer, produced similar results.

In our analysis, the PFS in all four studies were significantly increased by BV. We noted that in E2100, RIBBON-2, and RIBBON-1, there were subgroups that dealt with TNBC. We did a subgroup analysis that also revealed a statistically significant increase in PFS, which was more significant than that in the HER2-negative population alone (HER2-neg 0.73 vs TNBC 0.56). Since there is no standard treatment yet for TNBC, bevacizumab seems to be an attractive option and has indeed been explored in several studies, but these were all in the neoadjuvant (NCT00861705, NCT00786798) or adjuvant setting (NCT00528567). Results for ORR were homogenous and statistically significant in favour of BV in HER2-negative breast cancer. OS did not reach statistical significance and was heterogeneous, with only E2100 showing an increase in OS. Some argue that this was probably due to the effect of weekly paclitaxel, but there has never been another trial that confirmed this. Since we did not have access to raw data, we had to statistically derive our values.

The results of our study mirror the results of an earlier meta-analysis on E2100, AVADO, and RIBBON-1. Our independent review reflects the same conclusions, even with the addition of RIBBON-2. The funnel plots below show this (Figure 7).
Review: Bevacizumab in HER2-negative locally-recurrent and metastatic breast cancer: The BHerN Review
Comparison: Bevacizumab plus chemotherapy vs Chemotherapy alone in HER2-negative locally recurrent and metastatic breast cancer
Outcome: Progression-free survival

Review: Bevacizumab in HER2-negative locally-recurrent and metastatic breast cancer: The BHerN Review
Comparison: Bevacizumab plus chemotherapy vs Chemotherapy alone in triple-negative locally recurrent and metastatic breast cancer
Outcome: Progression-free survival

Figure 7. Funnel plots for PFS in HER2-negative and TNBC

As expected, adverse events were increased in all BV arms but fatal toxicities were not increased. There was a minimal increase in the incidence of hypertension, venous thromboembolism, and neutropenia. Bleeding events happened in <5% of the population. In E2100, the only patient with a grade 5 event was a patient in the BV arm who suffered from a ruptured diverticulum. No grade 5 events were reported in AVADO, RIBBON-1, and RIBBON-2. Majority of deaths in all four trials were related to disease-progression and those not related to progression balanced out in both arms.

We differ from other reviews in that our meta-analysis only included data from randomized Phase III trials. We included the objective response rates. We included only the purely HER2-negative population (excluded the HER2-positive that progressed on trastuzumab or those that were using trastuzumab or those that were HER2-unknown) in the survival data. Efficacy and safety data were pooled regardless of whether it was first- or second-line chemotherapy. Nevertheless, hazard ratios of all of our findings for both PFS and OS are comparable.

The major limitation in our meta-analysis is the variability of the added chemotherapy to BV across all studies. We think that this is also the reason why the studies were heterogenous. E2100 used paclitaxel. AVADO used docetaxel. RIBBON-1 combined taxane with anthracycline or capecitabine. RIBBON-2 was more liberal with the preference of chemotherapy leaving the choice solely to the physician. This made it harder to generalize the benefit for all patients included in the analysis. However, shifting to random effects, the advantage was consistent in all studies. In the real world, this would really be the scenario since most of the patients with metastases have probably been given more than one chemotherapy regimen already that would preclude the usage of a drug used in the trials.

Her2 (-) breast cancer is also a heterogenous group of tumors that include hormonal sensitive (ER and/or PR positive tumors) as well as triple negative variants (ER, PR, Her 2 negative). Because of this, overall behaviour and patient prognosis may differ, with the hormonal sensitive variants tending to have slower growth, less propensity for visceral metastases, longer remission periods and better overall prognosis for survival compared to the triple negative variants. Hence looking at results mostly as Her2 alone may not completely evaluate the value of this combination, since the population of hormonal sensitive patients would have better prognosis and skew results to the positive side. This may be the main reason for failure to see an improvement in OS and not just the heterogeneity of chemotherapy.

Burstein15 criticized the outcomes of E2100, AVADO, and RIBBON-1. Although statistically significant, he wrote that these trials produced outcomes that were arguably, not compelling since OS was not increased. However, more than three-fourths of oncology drugs are already approved for use based on surrogate endpoints (PFS, TTP, ORR, instead of OS). In an effort to accelerate cancer drug development and to decrease the time before a new effective agent is made available to patients, these surrogate endpoints are of vital importance. This too justifies the favourable results of our meta-analysis, even if the benefit was limited to PFS and ORR. We think that the addition of BV to conventional first- or second-line chemotherapy is justified in HER2-negative mBC, and more so in TN negative
mBC since there is still no standard treatment for this. As always, however, economics has also to be factored in the decision to use BV for a patient in need.

References
### Appendix 1. Characteristics of Excluded Trials

<table>
<thead>
<tr>
<th>Study</th>
<th>Method</th>
<th>Participants</th>
<th>Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in Her-2 Negative, Hormone Receptor Negative Metastatic Breast Cancer</td>
<td>Cohort</td>
<td>Disease progression after at least one prior chemotherapy regimen for metastatic disease or within 12 months of adjuvant chemotherapy initiation</td>
<td>Bevacizumab, Abraxane</td>
<td>Primary: PFS, Secondary: RR</td>
</tr>
<tr>
<td>A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in Triple Negative Metastatic Breast Cancer</td>
<td>Cohort</td>
<td>Patients may have received 0 - 1 prior therapies (except taxanes in the metastatic setting)</td>
<td>Abraxane Bevacizumab Carboplatin</td>
<td>Primary: Safety, Secondary: PFS</td>
</tr>
<tr>
<td>Adjuvant Doxorubicin, Cyclophosphamide Followed by Avastin Given With Paclitaxel and Gemcitabine for Stage II and III Breast Cancer That Does Not Over-express HER-2/Neu</td>
<td>Cohort</td>
<td>HER2-negative Breast Cancer Stage II to Breast Cancer Stage IIIIC</td>
<td>doxorubicin cyclophosphamide bevacizumab paclitaxel gemcitabine</td>
<td>Primary: Feasibility, DFS, OS</td>
</tr>
<tr>
<td>Docetaxel-epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 Negative Breast Cancer. A Multicenter Phase I-II Study</td>
<td>Cohort</td>
<td>HER2-negative Breast Cancer</td>
<td>Docetaxel Epirubicin Bevacizumab</td>
<td>Primary: ORR, Secondary: Toxicity, TTP, OS</td>
</tr>
<tr>
<td>AVF 2119</td>
<td>RCT</td>
<td>Previously Treated Metastatic Breast Cancer</td>
<td>Bevacizumab</td>
<td>Primary: Efficacy, Safety</td>
</tr>
<tr>
<td>Sabre-B</td>
<td>RCT</td>
<td>Metastatic Breast Cancer</td>
<td>Bevacizumab sunitinib paclitaxel</td>
<td>Primary: Best response, Secondary: SAEs</td>
</tr>
<tr>
<td>Study of Avastin (Bevacizumab) and Sequential Chemotherapy in Patients With Primary HER2 Negative Operable Breast Cancer</td>
<td>Non-RCT</td>
<td>Operable Her2 negative breast CA</td>
<td>bevacizumab Docetaxel Standard chemotherapy</td>
<td>Primary: Pathologic complete response, Secondary: ORR</td>
</tr>
<tr>
<td>A Multi Phase II Clinical Trials Evaluating the Association of Bevacizumab With Weekly Paclitaxel and Capecitabine in First Line Treatment for Patients With Triple Negative Metastatic or Locally Advanced Cancer</td>
<td>Non-RCT</td>
<td>Triple Negative Metastatic Breast Cancer</td>
<td>Paclitaxel Bevacizumab Capecitabine</td>
<td>Primary: ORR</td>
</tr>
</tbody>
</table>

### Appendix 2. Characteristic of Ongoing Studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Method</th>
<th>Participants</th>
<th>Intervention</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer</td>
<td>Cohort</td>
<td>Women with previously untreated metastatic breast cancer, ER/PR/HER2/neu negative</td>
<td>Doxil Carboplatin Bevacizumab</td>
<td>Primary: PFS, Secondary: RR</td>
</tr>
<tr>
<td>A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC)</td>
<td>RCT</td>
<td>HER2-negative breast cancer No prior chemotherapy for MBC</td>
<td>Everolimus Bevacizumab Paclitaxel Placebo</td>
<td>Primary: PFS, Secondary: RR, CR, PR</td>
</tr>
<tr>
<td>A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer</td>
<td>RCT</td>
<td>breast cancer must be HER2-negative based on current ASCO/CAP Guideline Recommendations</td>
<td>bevacizumab Drug: docetaxel Drug: doxorubicin Drug: cyclophosphamide Drug: pegfilgrastim</td>
<td>Primary: IDFS, Secondary: DFS-DCIS</td>
</tr>
<tr>
<td>Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2-Inflammatory Breast Cancer</td>
<td>Cohort</td>
<td>HER2-negative, inflammatory breast cancer</td>
<td>bevacizumab cyclophosphamide doceatxel epirubicin hydrochloride fluorouracil</td>
<td>Primary: HRR, PFS, OS</td>
</tr>
<tr>
<td>Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients</td>
<td>RCT</td>
<td>Locally Recurrent and Metastatic Breast Cancer, Her2 negative</td>
<td>AMG 386 Bevacizumab Paclitaxel</td>
<td>Primary: PFS, Secondary: DOR, TTP, OR</td>
</tr>
<tr>
<td>BEATRICE Study</td>
<td>RCT</td>
<td>TNBC</td>
<td>bevacizumab Standard adjuvant chemotherapy</td>
<td>Primary: Invasive DFS, Secondary Outcome: OS, DFS</td>
</tr>
</tbody>
</table>